BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22743654)

  • 1. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients.
    Sukov WR; Hodge JC; Lohse CM; Akre MK; Leibovich BC; Thompson RH; Cheville JC
    Mod Pathol; 2012 Nov; 25(11):1516-25. PubMed ID: 22743654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review.
    Yu W; Wang Y; Jiang Y; Zhang W; Li Y
    Histopathology; 2017 Jul; 71(1):53-62. PubMed ID: 28199742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients.
    Sukov WR; Hodge JC; Lohse CM; Leibovich BC; Thompson RH; Pearce KE; Wiktor AE; Cheville JC
    Am J Surg Pathol; 2012 May; 36(5):663-70. PubMed ID: 22498819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
    Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
    Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.
    Jia SW; Fu S; Wang F; Shao Q; Huang HB; Shao JY
    World J Gastroenterol; 2014 Jan; 20(1):183-92. PubMed ID: 24415871
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Wangsiricharoen S; Zhong M; Ranganathan S; Matoso A; Argani P
    Int J Surg Pathol; 2021 Oct; 29(7):808-814. PubMed ID: 33729862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.
    Jeanneau M; Gregoire V; Desplechain C; Escande F; Tica DP; Aubert S; Leroy X
    Pathol Res Pract; 2016 Nov; 212(11):1064-1066. PubMed ID: 27554841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217.
    Kuroda N; Trpkov K; Gao Y; Tretiakova M; Liu YJ; Ulamec M; Takeuchi K; Agaimy A; Przybycin C; Magi-Galluzzi C; Fushimi S; Kojima F; Sibony M; Hang JF; Pan CC; Yilmaz A; Siadat F; Sugawara E; Just PA; Ptakova N; Hes O
    Mod Pathol; 2020 Dec; 33(12):2564-2579. PubMed ID: 32467651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
    Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
    Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy?
    Smith NE; Deyrup AT; Mariño-Enriquez A; Fletcher JA; Bridge JA; Illei PB; Netto GJ; Argani P
    Am J Surg Pathol; 2014 Jun; 38(6):858-63. PubMed ID: 24698962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.
    Sugawara E; Togashi Y; Kuroda N; Sakata S; Hatano S; Asaka R; Yuasa T; Yonese J; Kitagawa M; Mano H; Ishikawa Y; Takeuchi K
    Cancer; 2012 Sep; 118(18):4427-36. PubMed ID: 22252991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
    Camidge DR; Theodoro M; Maxson DA; Skokan M; O'Brien T; Lu X; Doebele RC; Barón AE; Varella-Garcia M
    Cancer; 2012 Sep; 118(18):4486-94. PubMed ID: 22282074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
    Camidge DR; Skokan M; Kiatsimkul P; Helfrich B; Lu X; Barón AE; Schulte N; Maxson D; Aisner DL; Franklin WA; Doebele RC; Varella-Garcia M
    Cancer; 2013 Nov; 119(22):3968-75. PubMed ID: 24022839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review.
    Yang J; Dong L; Du H; Li XB; Liang YX; Liu GR
    Diagn Pathol; 2019 Oct; 14(1):112. PubMed ID: 31627758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey.
    Doğan K; Onder E
    Pathol Res Pract; 2024 Jan; 253():154951. PubMed ID: 38039739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK-rearranged renal cell carcinomas in Polish population.
    Gorczynski A; Czapiewski P; Korwat A; Budynko L; Prelowska M; Okon K; Biernat W
    Pathol Res Pract; 2019 Dec; 215(12):152669. PubMed ID: 31677810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas.
    Nishino M; Klepeis VE; Yeap BY; Bergethon K; Morales-Oyarvide V; Dias-Santagata D; Yagi Y; Mark EJ; Iafrate AJ; Mino-Kenudson M
    Mod Pathol; 2012 Nov; 25(11):1462-72. PubMed ID: 22743652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum.
    Debelenko LV; Raimondi SC; Daw N; Shivakumar BR; Huang D; Nelson M; Bridge JA
    Mod Pathol; 2011 Mar; 24(3):430-42. PubMed ID: 21076462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
    Cao Q; Chen M; Li Z; Huang W; Jin Y; Ye X; Tong M
    Clin Lab; 2016; 62(1-2):179-86. PubMed ID: 27012048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.